Hemostemix Free Cash Flow Yield vs Pfcf Ratio Analysis

HEM Stock

CAD 0.08 0.01 11.11%

Hemostemix financial indicator trend analysis is much more than just examining Hemostemix latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hemostemix is a good investment. Please check the relationship between Hemostemix Free Cash Flow Yield and its Pfcf Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Free Cash Flow Yield vs Pfcf Ratio

Free Cash Flow Yield vs Pfcf Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hemostemix Free Cash Flow Yield account and Pfcf Ratio. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Hemostemix's Free Cash Flow Yield and Pfcf Ratio is -0.62. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Pfcf Ratio in the same time period over historical financial statements of Hemostemix, assuming nothing else is changed. The correlation between historical values of Hemostemix's Free Cash Flow Yield and Pfcf Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Hemostemix are associated (or correlated) with its Pfcf Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pfcf Ratio has no effect on the direction of Free Cash Flow Yield i.e., Hemostemix's Free Cash Flow Yield and Pfcf Ratio go up and down completely randomly.

Correlation Coefficient

-0.62

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Pfcf Ratio

Most indicators from Hemostemix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hemostemix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Issuance Of Capital Stock is likely to climb to about 2.3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 1.3 M in 2024.

Hemostemix fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Current Deferred Revenue
Total Assets		-0.31	-0.38	0.73	0.73	-0.02	-0.78	0.22	-0.17	0.94	-0.02	-0.13	0.95	0.21	-0.33	-0.2	0.18	-0.31	-0.44	0.07	1.0	0.2	-0.01	-0.01	-0.24	0.0
Other Current Liab	-0.31		0.71	-0.78	-0.73	-0.71	0.76	-0.87	0.57	-0.43	-0.7	0.63	-0.41	0.34	0.82	0.72	-0.42	0.9	0.86	-0.71	-0.27	-0.13	0.78	-0.71	0.44	-0.77
Total Current Liabilities	-0.38	0.71		-0.75	-0.79	-0.7	0.61	-0.76	0.8	-0.44	-0.72	0.66	-0.41	0.23	0.57	0.79	-0.69	0.72	0.77	-0.5	-0.33	-0.49	0.73	-0.69	0.19	-0.68
Total Stockholder Equity	0.73	-0.78	-0.75		0.99	0.54	-0.97	0.8	-0.52	0.7	0.54	-0.59	0.68	0.11	-0.84	-0.7	0.42	-0.84	-0.94	0.6	0.69	0.41	-0.63	0.54	-0.59	0.58
Net Tangible Assets	0.73	-0.73	-0.79	0.99		0.54	-0.94	0.79	-0.56	0.71	0.54	-0.56	0.69	0.09	-0.8	-0.69	0.45	-0.82	-0.91	0.53	0.7	0.5	-0.63	0.54	-0.53	0.59
Property Plant And Equipment Net	-0.02	-0.71	-0.7	0.54	0.54		-0.43	0.89	-0.65	0.02	1.0	-0.79	-0.03	-0.16	-0.7	-0.89	0.73	-0.79	-0.72	0.67	-0.09	0.34	-0.93	1.0	-0.46	0.97
Net Debt	-0.78	0.76	0.61	-0.97	-0.94	-0.43		-0.7	0.36	-0.76	-0.42	0.49	-0.74	-0.14	0.79	0.59	-0.31	0.76	0.87	-0.54	-0.75	-0.25	0.5	-0.43	0.6	-0.47
Retained Earnings	0.22	-0.87	-0.76	0.8	0.79	0.89	-0.7		-0.68	0.26	0.88	-0.79	0.23	-0.12	-0.92	-0.89	0.57	-0.97	-0.93	0.78	0.17	0.44	-0.96	0.89	-0.59	0.93
Accounts Payable	-0.17	0.57	0.8	-0.52	-0.56	-0.65	0.36	-0.68		-0.28	-0.64	0.6	-0.26	0.4	0.54	0.63	-0.64	0.69	0.58	-0.46	-0.13	-0.69	0.69	-0.64	0.0	-0.69
Cash	0.94	-0.43	-0.44	0.7	0.71	0.02	-0.76	0.26	-0.28		0.02	-0.13	0.99	-0.1	-0.33	-0.23	0.25	-0.36	-0.43	0.02	0.94	0.18	-0.07	0.04	-0.09	0.08
Non Current Assets Total	-0.02	-0.7	-0.72	0.54	0.54	1.0	-0.42	0.88	-0.64	0.02		-0.8	-0.04	-0.15	-0.68	-0.89	0.73	-0.77	-0.72	0.66	-0.09	0.33	-0.92	0.99	-0.45	0.95
Other Assets	-0.13	0.63	0.66	-0.59	-0.56	-0.79	0.49	-0.79	0.6	-0.13	-0.8		-0.08	0.0	0.62	0.91	-0.75	0.67	0.69	-0.71	-0.08	-0.21	0.85	-0.78	0.54	-0.72
Cash And Short Term Investments	0.95	-0.41	-0.41	0.68	0.69	-0.03	-0.74	0.23	-0.26	0.99	-0.04	-0.08		-0.11	-0.31	-0.16	0.16	-0.34	-0.41	0.01	0.95	0.17	-0.03	-0.02	-0.06	0.04
Net Receivables	0.21	0.34	0.23	0.11	0.09	-0.16	-0.14	-0.12	0.4	-0.1	-0.15	0.0	-0.11		-0.02	0.04	-0.15	0.17	-0.05	0.11	0.22	0.03	0.2	-0.16	-0.53	-0.26
Common Stock Shares Outstanding	-0.33	0.82	0.57	-0.84	-0.8	-0.7	0.79	-0.92	0.54	-0.33	-0.68	0.62	-0.31	-0.02		0.71	-0.32	0.96	0.94	-0.77	-0.28	-0.46	0.8	-0.7	0.67	-0.79
Inventory	-0.2	0.72	0.79	-0.7	-0.69	-0.89	0.59	-0.89	0.63	-0.23	-0.89	0.91	-0.16	0.04	0.71		-0.84	0.78	0.8	-0.73	-0.15	-0.37	0.89	-0.88	0.47	-0.84
Other Current Assets	0.18	-0.42	-0.69	0.42	0.45	0.73	-0.31	0.57	-0.64	0.25	0.73	-0.75	0.16	-0.15	-0.32	-0.84		-0.46	-0.45	0.44	0.13	0.37	-0.61	0.72	-0.05	0.62
Other Stockholder Equity	-0.31	0.9	0.72	-0.84	-0.82	-0.79	0.76	-0.97	0.69	-0.36	-0.77	0.67	-0.34	0.17	0.96	0.78	-0.46		0.94	-0.75	-0.26	-0.48	0.88	-0.79	0.54	-0.88
Total Liab	-0.44	0.86	0.77	-0.94	-0.91	-0.72	0.87	-0.93	0.58	-0.43	-0.72	0.69	-0.41	-0.05	0.94	0.8	-0.45	0.94		-0.77	-0.39	-0.43	0.81	-0.72	0.64	-0.75
Long Term Investments	0.07	-0.71	-0.5	0.6	0.53	0.67	-0.54	0.78	-0.46	0.02	0.66	-0.71	0.01	0.11	-0.77	-0.73	0.44	-0.75	-0.77		0.03	0.25	-0.7	0.65	-0.49	0.63
Total Current Assets	1.0	-0.27	-0.33	0.69	0.7	-0.09	-0.75	0.17	-0.13	0.94	-0.09	-0.08	0.95	0.22	-0.28	-0.15	0.13	-0.26	-0.39	0.03		0.18	0.05	-0.08	-0.21	-0.06
Intangible Assets	0.2	-0.13	-0.49	0.41	0.5	0.34	-0.25	0.44	-0.69	0.18	0.33	-0.21	0.17	0.03	-0.46	-0.37	0.37	-0.48	-0.43	0.25	0.18		-0.38	0.34	0.01	0.42
Common Stock	-0.01	0.78	0.73	-0.63	-0.63	-0.93	0.5	-0.96	0.69	-0.07	-0.92	0.85	-0.03	0.2	0.8	0.89	-0.61	0.88	0.81	-0.7	0.05	-0.38		-0.92	0.54	-0.95
Property Plant Equipment	-0.01	-0.71	-0.69	0.54	0.54	1.0	-0.43	0.89	-0.64	0.04	0.99	-0.78	-0.02	-0.16	-0.7	-0.88	0.72	-0.79	-0.72	0.65	-0.08	0.34	-0.92		-0.46	0.97
Short Long Term Debt Total	-0.24	0.44	0.19	-0.59	-0.53	-0.46	0.6	-0.59	0.0	-0.09	-0.45	0.54	-0.06	-0.53	0.67	0.47	-0.05	0.54	0.64	-0.49	-0.21	0.01	0.54	-0.46		-0.46
Current Deferred Revenue	0.0	-0.77	-0.68	0.58	0.59	0.97	-0.47	0.93	-0.69	0.08	0.95	-0.72	0.04	-0.26	-0.79	-0.84	0.62	-0.88	-0.75	0.63	-0.06	0.42	-0.95	0.97	-0.46

Click cells to compare fundamentals

Hemostemix Account Relationship Matchups

Hemostemix fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	104.3K	2.3M	563.0K	465.3K	313.8K	298.1K
Other Current Liab	2.1M	3.2M	1.0M	2.6M	3.0M	3.2M
Total Current Liabilities	4.1M	3.4M	4.4M	2.6M	2.9M	2.4M
Total Stockholder Equity	(4.0M)	(1.1M)	(5.3M)	(6.8M)	(7.4M)	(7.0M)
Net Tangible Assets	487.8K	(4.0M)	(1.1M)	(6.8M)	(6.1M)	(5.8M)
Net Debt	2.0M	(83.0K)	1.3M	4.0M	4.2M	4.4M
Retained Earnings	(41.5M)	(49.2M)	(55.5M)	(60.8M)	(63.3M)	(60.1M)
Accounts Payable	2.1M	3.2M	4.4M	2.4K	2.9M	1.6M
Cash	24.1K	258.0K	219.4K	135.7K	155.4K	147.6K
Non Current Assets Total	4.5K	2.0K	902.0	407.0	184.0	174.8
Cash And Short Term Investments	24.1K	258.0K	219.4K	135.7K	155.4K	147.6K
Net Receivables	75.8K	2.1M	342.7K	138.9K	25.1K	23.8K
Common Stock Shares Outstanding	15.0M	32.2M	57.4M	70.0M	82.5M	86.6M
Liabilities And Stockholders Equity	104.3K	2.3M	563.0K	465.3K	313.8K	298.1K
Inventory	(88.2K)	(13.3K)	(45.5K)	(342.7)	(394.1)	(413.81)
Other Current Assets	13.3K	45.5K	342.7	190.3K	133.1K	101.6K
Other Stockholder Equity	6.0M	8.7M	10.1M	10.2M	11.9M	12.5M
Total Liab	4.1M	3.4M	5.8M	7.2M	7.7M	8.1M
Total Current Assets	99.8K	2.3M	562.1K	464.9K	313.6K	297.9K
Accumulated Other Comprehensive Income	439.7K	1.5M	1.5M	2.7M	1.5M	1.5M
Net Invested Capital	(2.0M)	(923.7K)	(3.8M)	(2.6M)	(3.0M)	(2.9M)
Net Working Capital	(4.0M)	(1.1M)	(3.8M)	(2.2M)	(2.6M)	(2.4M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Hemostemix Stock Analysis

When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC